ACTIPATCH WILL BE A "STANDARD OF CARE" PRODUCT! W
Post# of 8286
(Total Views: 43)
Posted On: 05/12/2025 11:54:59 PM
ACTIPATCH WILL BE A "STANDARD OF CARE" PRODUCT!
With FDA clearance for treatment of knee, back, wrist, hips, ankles, plantar fasciitis and all musculoskeletal pain, how can it not, especially at the low price of $35 - with a much longer battery life than the competition! The Actipatch FDA clearance allows it to be sold over the counter (without a prescription). The RecoveryRX applications (post operative pain, edema, wound care, etc.) do require a doctor order. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet (every month). Then there is the "wellness" market, as many people use Actipatch for Restless Leg Syndrome (RLS is estimated to affect 10% of adults worldwide), menstrual pain, migraines and other "off label" aches and pains.
POTENTIAL
The potential is mind-boggling - especially if Actipatch is identified as a "wellness product" for the applications not currently covered by the FDA clearances.
From the 2024 Annual Report:
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.
The chronic pain market is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers. The Company’s medical devices modulate the body’s nerve activity to dampen the pain perception, which reduces drug use. RecoveryRx will be an ideal choice in reducing postoperative pain and exposure to long-term effects of opioid/NSAID therapy.
The technology has the potential to become the standard of care throughout the healthcare continuum across the OTC and healthcare markets. BioElectronics’ technology offers significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.
In February 2020, BioElectronics obtained a new 510(k) clearance from the U.S. FDA, granting over-the-counter marketing clearance for the drug-free ActiPatch medical device, to cover all musculoskeletal pain complaints. This paves the way for new products to treat all medical claims for musculoskeletal pain, including in the back, knee, hips, wrists, elbow, and ankle.
RECOVERYRX-VETERINARY COULD/SHOULD BE A GOLDMINE!
The Assisi Loop sells over 300/month just on Amazon @ $329, with 1/20 the battery life. Assisi Loop customers are paying the equivalent of over $6,000 when you factor in the additional cost and lower battery life, but Assisi customers seem happy to pay it based on the numerous 5-star reviews. RecoveryRx/Veterinary should be sold as a two/pack - one for the vagus nerve and the other for the area of pain.
With FDA clearance for treatment of knee, back, wrist, hips, ankles, plantar fasciitis and all musculoskeletal pain, how can it not, especially at the low price of $35 - with a much longer battery life than the competition! The Actipatch FDA clearance allows it to be sold over the counter (without a prescription). The RecoveryRX applications (post operative pain, edema, wound care, etc.) do require a doctor order. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet (every month). Then there is the "wellness" market, as many people use Actipatch for Restless Leg Syndrome (RLS is estimated to affect 10% of adults worldwide), menstrual pain, migraines and other "off label" aches and pains.
POTENTIAL
The potential is mind-boggling - especially if Actipatch is identified as a "wellness product" for the applications not currently covered by the FDA clearances.
From the 2024 Annual Report:
BioElectronics is an electroceutical company that develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Our innovative pulsed shortwave therapy technology (PSWT) that uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.
The chronic pain market is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers. The Company’s medical devices modulate the body’s nerve activity to dampen the pain perception, which reduces drug use. RecoveryRx will be an ideal choice in reducing postoperative pain and exposure to long-term effects of opioid/NSAID therapy.
The technology has the potential to become the standard of care throughout the healthcare continuum across the OTC and healthcare markets. BioElectronics’ technology offers significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation, and other applications.
In February 2020, BioElectronics obtained a new 510(k) clearance from the U.S. FDA, granting over-the-counter marketing clearance for the drug-free ActiPatch medical device, to cover all musculoskeletal pain complaints. This paves the way for new products to treat all medical claims for musculoskeletal pain, including in the back, knee, hips, wrists, elbow, and ankle.
RECOVERYRX-VETERINARY COULD/SHOULD BE A GOLDMINE!
The Assisi Loop sells over 300/month just on Amazon @ $329, with 1/20 the battery life. Assisi Loop customers are paying the equivalent of over $6,000 when you factor in the additional cost and lower battery life, but Assisi customers seem happy to pay it based on the numerous 5-star reviews. RecoveryRx/Veterinary should be sold as a two/pack - one for the vagus nerve and the other for the area of pain.
(0)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼